The first and only FDA-approved therapy for
adults with prurigo nodularis (PN)
DUPIXENT was studied in 2 pivotal trials of adult patients with prurigo nodularis
≈3X
as many patients in PRIME had
significantly reduced itch at Week 24
(60% with DUPIXENT vs 18% with
placebo; P<0.001, primary endpoint)
PRIME2
37% of DUPIXENT patients achieved a meaningful
response at Week 12 vs 22% with placebo; P=0.022 (primary endpoint). At Week 24, 58% of DUPIXENT patients achieved significant itch relief vs 20% with placebo; P<0.001 (secondary endpoint)
≈2.5X
as many patients in PRIME achieved
significant nodule clearance
(IGA PN-S 0 or 1) at Week 24 (48% with
DUPIXENT vs 18% with placebo;
P<0.001, secondary endpoint)
PRIME2
45% of DUPIXENT patients similarly achieved significant nodule clearance (IGA PN-S 0 or 1) at Week 24 vs 16% with placebo; P<0.001 (secondary endpoint)
IGA PN-S, Investigator’s Global
Assessment PN-Stage.
DUPIXENT HAS A DEMONSTRATED
SAFETY PROFILE2
Most common adverse reactions in adult patients with prurigo nodularis (incidence ≥2%) were
nasopharyngitis, conjunctivitis, herpes infection, dizziness, myalgia, and diarrhea
The First and Only Therapy to Target IL‑4Rα, Thereby
SPECIFICALLY Inhibiting IL‑4 and IL‑13 Signaling2
The mechanism of dupilumab action has not been definitively established
Other attributes
NOT AN
IMMUNOSUPPRESSANT2
NO INITIAL LAB TESTING OR
ONGOING LAB MONITORING
according to the Prescribing Information2
NO KNOWN DRUG‑TO‑DRUG
INTERACTIONS2
- Not metabolized through the liver or
excreted through the kidneys
NO boxed warning2
Please see additional Warnings and
Precautions in the Prescribing Information
and Important Safety Information below.
Select Important Safety Information
Warnings and Precautions
- Hypersensitivity: Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions,
angioedema, generalized urticaria, rash, erythema nodosum, and erythema multiforme have been reported. If a clinically
significant hypersensitivity reaction occurs, institute appropriate therapy and discontinue DUPIXENT
Discover how DUPIXENT inhibits IL-4
and IL-13 signaling
The first and only FDA-approved therapy for
adults with prurigo nodularis (PN)
Help appropriate patients benefit from DUPIXENT
Review case studies to help identify appropriate patients in your practice
Extensive Real-World
Experience ACROSS DUPIXENT
In the us, studied in 17 pivotal trials across 5 indications2
Globally,
≈800,000
patients on DUPIXENT
therapy across 5
indications3,a
aThe worldwide patient number is largely comprised of patients treated with DUPIXENT from 10 countries (Canada, China, France, Germany, Italy, Japan, the Netherlands, Spain, UK, and US) and the rest of the world comprising ≈10% of this worldwide patient number. Data through December 2023.
DUPIXENT MyWay® is a patient support program that can help enable access to DUPIXENT and offers financial assistance for eligible patients, one-on-one nursing support, and more.